Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.
Cannabics Pharmaceuticals Inc is a biotechnology company. It develops pharmaceuticals focusing on cancer research utilizing advanced HTS technology and personalized bioinformatics tools. The company's main focus is the development of therapies and biotechnological tools aimed at diverse ailments and human malignancies. The firm's main product is the RCC-33, an oral capsule for the treatment of colorectal cancer. Its advanced tools include delivery systems, personalized medicine diagnostics, and therapies based on Cannabinoid compounds.
Bethesda, MD, 20814